Biocon Biologics Limited (BBL), a subsidiary of Biocon, on Thursday announced a strategic alliance with Serum Institute Life Sciences (SILS). As per the agreement, BBL will offer approximately 15% stake to SILS for access to a 100 million doses of vaccines per annum for 15 years. Adar Poonawalla will have a Board seat in Biocon Biologics Limited, the company said. In addition to vaccines, the strategic alliance will also develop antibodies targeting several infectious diseases like Dengue, HIV, etc. Biocon Biologics will also establish, at its cost, a vaccine R&D division to support the strategic alliance in developing both vaccines and biologics for communicable diseases.

Source: Mint September 16, 2021 17:21 UTC